Como prevenir y tratar las hipoglucemias farmacológicas

García, Rebeca Reyes; Raya, Pedro Mezquita

doi:10.1016/j.rce.2013.12.011

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current recommendations prioritize the selection of antidiabetic treatments with low risk of hypoglycemia, and also recommend considering the effects of antidiabetic drugs on weight when selecting a treatment [ 2 , 3 ]. The presence of hypoglycemic events resulted in increased use of health-care resources [ 4 ], so the selection of antidiabetic treatment with a low risk of hypoglycemia may result not only in an improvement in the quality of life, but also in a reduction in costs [ 4 ]. Considering these findings, in a recent position paper from the Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition [ 5 ], the use of GLP1RA as a second- or third-line therapy is recommended in type 2 DM patients with obesity due to its low risk of hypoglycemia and its additional effects beyond the improvement in glycated hemoglobin (HbA 1c ) and weight.…”

Section: Introductionmentioning

confidence: 99%

Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study

et al. 2015

View full text Add to dashboard Cite

IntroductionA limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under unreal conditions and in a very limited and highly selected patient population. Our aim was to provide data about the effectiveness of liraglutide treatment in a real-world and clinical practice setting.MethodsIn a retrospective and observational study, data from 753 patients with type 2 diabetes were recorded through an online tool (eDiabetes-Monitor).ResultsMean baseline glycated hemoglobin (HbA1c) was 8.4 ± 1.4% and mean body mass index (BMI) was 38.6 ± 5.4 kg/m2. After 3–6 months of treatment with liraglutide, we observed a change in HbA1c of −1.1 ± 1.2%, −4.6 ± 5.3 kg in weight and −1.7 ± 2.0 kg/m2 in BMI (p < 0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (−5.9 mmHg, p < 0.001), diastolic blood pressure (−3.2 mmHg, p < 0.001), LDL cholesterol (−0.189 mmol/l, p < 0.001) and triglycerides (−0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of −1.0% in HbA1c (p < 0.001) and a reduction in weight (−4.5 kg, p < 0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of −1.08% in HbA1c (p < 0.001) and a weight reduction of −4.15 kg (p < 0.001) were observed.ConclusionOur study confirms the effectiveness of liraglutide in a real-life and clinical practice setting.FundingSpanish Society of Endocrinology and Nutrition.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-015-0112-4) contains supplementary material, which is available to authorized users.

show abstract